Cerebellar atrophy decreases the threshold of carbamazepine toxicity in patients with chronic focal epilepsy.

BACKGROUND Cerebellar atrophy (CA) is a frequent finding in patients with chronic epilepsy. Since gaze-evoked nystagmus, dizziness, and ataxia are some of the typical adverse effects (AEs) of the dose-dependent toxicity of carbamazepine, preexisting CA could possible explain in part the interindividual variation in the tolerance of high serum concentrations of carbamazepine. OBJECTIVE To determine whether CA reduces the threshold for overdose symptoms with carbamazepine in patients with chronic focal epilepsy in a prospective study. DESIGN Cohort study. SETTING A fourth-level epilepsy center to which patients were referred. PATIENTS Twenty-six consecutive patients with chronic focal epilepsy were prospectively studied while they were receiving high-dose monotherapy with carbamazepine. Patients were slowly titrated to doses at which the first toxic AEs of carbamazepine occurred. The determination of multiple serum levels was carried out, together with an evaluation of toxicity that comprised a standardized neurologic examination, a questionnaire for AEs, and posturography. MAIN OUTCOME MEASURES Serum concentrations of carbamazepine at the occurrence of the first dose-dependent AEs were related to the presence or absence of CA in magnetic resonance imaging studies as rated by 2 independent and blinded neuroradiologists. RESULTS In 9 patients (35%), magnetic resonance imaging scans revealed moderate (n = 7) or severe (n = 2) CA. In these patients, gaze-evoked nystagmus (P = .001, log rank test), dizziness (P = .008), and ataxia of stance as measured by posturography (P = .02) occurred at significantly lower serum concentrations of carbamazepine compared with patients without CA. This was also found for the first individually observed AE (P = .03). CONCLUSION Cerebellar atrophy occurs in a considerable percentage of patients with chronic focal epilepsy and obviously increases the susceptibility for cerebellar AEs of carbamazepine.

[1]  E. Perucca,et al.  Lateral gaze nystagmus in carbamazepine-treated epileptic patients: correlation with total and free plasma concentrations of parent drug and its 10,11-epoxide metabolite. , 1985, Therapeutic drug monitoring.

[2]  A. Cohen,et al.  Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam. , 1985, British journal of clinical pharmacology.

[3]  M. Kurachi,et al.  Lennox-Gastaut syndrome with and without Dandy-Walker malformation , 1987, Epilepsy Research.

[4]  M. Iivanainen,et al.  Cerebellar Atrophy in Phenytoin‐Treated Mentally Retarded Epileptics , 1977, Epilepsia.

[5]  L. Cyr,et al.  Measures of clinical agreement for nominal and categorical data: the kappa coefficient. , 1992, Computers in biology and medicine.

[6]  T. May,et al.  Systematic Comparison of Three Basic Methods of Sample Pretreatment For High‐Performance Liquid Chromatographic Analysis of Antiepileptic Drugs Using Gas Chromatography as a Reference Method , 1984, Therapeutic drug monitoring.

[7]  W T Blume,et al.  Ataxia in Institutionalized Patients with Epilepsy , 1994, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[8]  P. Wolf,et al.  Cerebellar atrophy does not increase susceptibility to carbamazepine toxicity , 1994, Acta neurologica Scandinavica.

[9]  J. Dichgans,et al.  Idiopathic cerebellar ataxia of late onset: natural history and MRI morphology. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[10]  B. Weatherley,et al.  Carbamazepine and Lamotrigine in Healthy Volunteers: Relevance to Early Tolerance and Clinical Trial Dosage , 1993, Epilepsia.

[11]  A. Ebner,et al.  Systematic Testing of Medical Intractability for Carbamazepine, Phenytoin, and Phenobarbital or Primidone in Monotherapy for Patients Considered for Epilepsy Surgery , 1996, Epilepsia.

[12]  E. Perucca,et al.  Free and Total Plasma Concentrations of Carbamazepine and Carbamazepine‐10, 11‐Epoxide in Epileptic Patients: Diurnal Fluctuations and Relationship with Side Effects , 1984, Therapeutic drug monitoring.

[13]  Joachim Krauth,et al.  Distribution-Free Statistics: An Application-Oriented Approach , 1988 .

[14]  H. Henningsen,et al.  [Cerebellar atrophy in epileptic patients: computer tomography study]. , 1985, Fortschritte der Neurologie-Psychiatrie.

[15]  I. Savic,et al.  Localized cerebellar reductions in benzodiazepine receptor density in human partial epilepsy. , 1996, Archives of neurology.

[16]  M. Botez,et al.  Cerebellar Atrophy in Epileptic Patients , 1988, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[17]  T. Tomson.  Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. , 1984, Archives of neurology.

[18]  M. Dam.  Number of Purkinje Cells in Patients with Grand Mai Epilepsy treated with Diphenylhydantoin , 1970, Acta neurologica Scandinavica.

[19]  Reynolds Eh.  Neurotoxicity of carbamazepine. , 1975 .

[20]  G Lantos,et al.  Cerebellar atrophy in patients with long-term phenytoin exposure and epilepsy. , 1994, Archives of neurology.

[21]  D. King,et al.  Cerebellar atrophy in epilepsy and headache , 1982, Neurology.

[22]  R. Leigh,et al.  The characteristics and mechanisms of visual disturbance associated with anticonvulsant therapy , 1990, Neurology.